Compound ID | 85
FSI-1686
Class: Beta-lactam (carbapenem)
| Spectrum of activity: | Gram-negative |
| Details of activity: | MDR gram-negative infections |
| Institute where first reported: | AstraZeneca (UK) + FOB Synthesis, Inc (USA) |
| Year first mentioned: | 2014 |
| Highest developmental phase: | Preclinical |
| Development status: | Experimental |
| External links: | |
| Citations: |
|
AntibioticDB is supported by GARDP.
If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions
The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.